About Kevin
Expertise
Kevin Chang is the head of our Greater China Healthcare practice and a member of our Private Equity practice, based in Hong Kong.
Kevin regularly advises clients on organization, strategy and transformation, as well as both commercial and launch excellence. His recent client engagements have involved due diligence and sector screening and review efforts for private equity clients, as well as adjacency and business unit strategy across pharmaceuticals and biotechnology.
While with the firm, Kevin has led a commercial excellence exercise for one of the world's leading IVD manufacturers, which doubled the company’s business in China in 5 years.
He is also deeply involved with our local pro bono efforts.
Kevin holds a B.A. in Economics from Cornell University.
Recent Insights
- “Healthcare Private Equity in Asia-Pacific: A Multiyear Growth Trajectory ,” Report, March 2022
- “Medtech: The Pandemic Has Expanded Needs and Opportunities ,” Report, March 2022
- “Healthcare IT: Faster, Smarter, Tuned to Value ,” Report, March 2022
- “The New Board Agenda,” Brief, October 2021
- “China, Deglobalization, and the Multinational,” Article, July 2021